VYNE Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
MRKMerck & Co., Inc. 2.33%78.950.7%$1567.92m
JNJJohnson & Johnson 3.04%164.980.7%$1007.48m
PFEPfizer Inc. 1.94%42.120.9%$934.53m
ABBVAbbVie, Inc. 0.38%107.841.9%$684.53m
BMYBristol-Myers Squibb Co. 1.08%57.561.0%$658.46m
LLYEli Lilly & Co. 1.09%241.591.1%$616.01m
AZNAstraZeneca Plc 1.82%60.371.0%$372.97m
NVSNovartis AG 1.02%83.180.2%$176.13m
GSKGlaxoSmithKline Plc 1.67%39.300.2%$162.66m
RGENRepligen Corp. 2.28%269.796.8%$120.64m
NVONovo Nordisk A/S 1.51%104.990.1%$91.99m
VTRSViatris, Inc. 0.15%13.510.0%$90.70m
EDSAEdesa Biotech, Inc. 5.81%8.190.0%$74.98m
SNYSanofi 0.04%48.050.2%$62.90m
CRVSCorvus Pharmaceuticals, Inc. 3.46%4.780.7%$58.45m

Company Profile

Menlo Therapeutics is a clinical late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for refractory chronic cough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor (NK1-R) given as a once-daily, oral tablet, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms. Pruritus is the primary patient complaint among atopic dermatitis, psoriasis and prurigo nodularis patients and represents a significant patient need. There are currently no therapies approved in the US that are primarily intended to reduce the pruritus associated with these conditions. We expect data from our ongoing Phase 2 clinical trial in pruritus associated with atopic dermatitis in the 2Q18 and from our ongoing Phase 2 clinical trials in pruritus associated with psoriasis and refractory chronic cough by late 2018 or early 2019. We plan to initiate two Phase 3 clinical trials in pruritus associated with prurigo nodularis in the 1H18, with results expected in the 1H20.